OTHER FUNCTIONS NANOSORT"PHASE I, TOPIC 309, FLOWNOSTICS: PORTABLE MULTIPLEX ANA

癌症是一种复杂而多样的疾病，其治疗可以通过更复杂的早期检测和监测来改善。NanoSort公司提出建立一个芯片实验室微流控装置平台，可以检测和定量多达32种多重分析物，用于检测和监测血液或尿液样本中的癌症。这种新型的“FlowNostics”装置将利用32种微观珠粒，按其大小和颜色进行编码，这些珠粒将通过阻抗和单个光学检测器的组合来检测，以检测来自单个激光激发的发射。NanoSort的FlowNostics平台将降低基于流式细胞术的多重检测的费用和复杂性，以增加访问和护理点诊断。 NanoSort的FlowNostics技术将改善公共健康，并有助于实现NIH和NCI的使命，通过以当前设备的一小部分成本和复杂性改善对复杂分析的访问。NanoSort的目标是使在检查期间采集的常规血液样本能够报告癌症的存在，这将有助于早期发现癌症，并允许在癌症达到晚期之前进行治疗。

Cancer is a complex and diverse disease whose treatment can be improved by more sophisticated early detection and monitoring. NanoSort, Inc. proposes to build a lab-on-a-chip microfluidic device platform that can detect and quantify up to 32 multiplexed analytes for the detection and monitoring of cancer from blood or urine samples. This novel "FlowNostics" device will utilize 32 kinds of microscopic beads, coded by their size and color, that will be detected by a combination of impedence and a single optical detector to detect emission from single laser excitation. NanoSort's FlowNostics platform will reduce the expense and complexity of flow cytometric-based multiplex assays to increase access and point-of-care diagnostics. NanoSort's FlowNostics technology will improve public health and help to fulfill the mission of the NIH and NCI by improving access to sophisticated analytics at a fraction of the cost and complexity of current devices. NanoSort's aim is to make routine blood samples taken during check-ups capable of reporting the presence of cancer, which will aid in the early detection of cancer and allow treatments before cancers have reached an advanced stage.